Buy & Sell Iron Mountain Inc (IRM) – Iron Mountain Inc Price Today
Aura AI Summary
Key Stats
- $36.88BMarket Cap
- Real EstateSector
- -13.81%3M Drawdown
- $56.02BEnterprise Value
- 2.79%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 79 daysTypical Hold Time
Iron Mountain Inc (IRM) is currently valued at a market capitalization of $36.88B, with an enterprise value of $56.02B. Over the past 52 weeks, Iron Mountain Inc has traded between a low of $78.86 and a high of $132.06, highlighting its annual price range. Over the past three months, Iron Mountain Inc has recorded a drawdown of -13.81%, reflecting recent price volatility. Iron Mountain Inc offers a dividend yield of 2.79%, with the most recent dividend of $0.86 paid on 16 Mar 26. On average, investors hold Iron Mountain Inc for approximately 79 days, indicating typical investor behavior on the platform.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Most Recent News
Short seller warns Everspin stock is overvalued amid AI hype, predicts 60% downside.
Kerrisdale Capital has taken a short position on Everspin Technologies, arguing the recent surge in its stock price is driven by misplaced enthusiasm around AI-related memory demand. Everspin's MRAM technology targets niche industrial markets rather ...

Vuzix showcases advanced waveguide smart glasses for defense at SOF Week 2026 in Florida
Vuzix Corporation is exhibiting its advanced AI-powered smart glasses and waveguide solutions at SOF Week 2026 in Tampa, Florida. These products are designed for defense use, offering mission-ready optical performance in challenging environments, inc...

Over 50 companies advance 55+ new pulmonary arterial hypertension drugs in clinical trials.
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
